Publisher's Note The Review Article by Kunz, entitled, "Carcinoid and Neuroendocrine Tumors: Building on Success" (J Clin Oncol 10.1200/JCO.2014.60.2532), was published online April 27, 2015, with ...

A phase II trial of adjuvant UFT after sequential chemotherapy and radiotherapy in patients with stage IIIB non-small cell lung cancer and non-oriental ethnicity No significant financial relationships ...

Symptoms of neuroendocrine tumors (NETs) can vary depending on their location and severity. General symptoms include extreme fatigue, unexplained weight loss, and loss of appetite. NETs are a rare ...

Patients with neuroendocrine tumors or neuroblastoma could be treated with a different approach based on a protein that may be a potential biomarker. A specific protein could be a potential biomarker ...

“The regulatory approvals of cabozantinib in the United States and European Union earlier this year provide a much-needed targeted treatment option for patients with previously treated advanced NET,” ...

CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community ...

Dr. Elliott Winford (Medicine): An 86-year-old man was admitted to this hospital because of shortness of breath. The patient had been in his usual state of health until 6 months before the current ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin ...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 – CABOMETYX ...